Richard A. Larson
0000-0001-9168-3203
Publication & Citation Trends
Publications
0 total
Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors.
Cited by 0
Semantic Scholar
Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia.
Cited by 1
Semantic Scholar
Magrolimab plus azacitidine vs physician’s choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study OA
Cited by 39
Semantic Scholar
Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group & Alliance for Clinical Trials in Oncology)
Cited by 1
Semantic Scholar
Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia OA
Cited by 2
Semantic Scholar
Outcomes of patients with relapsed/refractory acute leukaemia treated with revumenib with a focus on post‐revumenib therapies
Cited by 0
Semantic Scholar
Asciminib Demonstrates Superior Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia in the ASC4FIRST Trial.
Cited by 3
Semantic Scholar
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Cited by 52
Semantic Scholar
Research Topics
Acute Myeloid Leukemia Research
(617)
Chronic Myeloid Leukemia Treatments
(422)
Acute Lymphoblastic Leukemia research
(354)
Chronic Lymphocytic Leukemia Research
(320)
Myeloproliferative Neoplasms: Diagnosis and Treatment
(115)
Affiliations
Northwestern University
University of North Carolina at Chapel Hill
Goethe University Frankfurt
Tufts University
University of Iowa